- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03840408
Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer
February 18, 2019 updated by: Ming Li, Shanghai 10th People's Hospital
Prospective Clinical Study of Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer
Lung cancer is the leading cause of cancer related mortality.
Among them, non small cell lung cancer accounts for 85%.
Only part of patients could be treated with radical surgery.
Mitochondria-targeted system therapy combined with radiofrequency ablation could be an alternative treatment.
Small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period.
The primary aim of this trial is to determine if the efficacy of mitochondria-targeted system therapy combined with radiofrequency ablation is comparable to that of standard surgical interventions for patients with non-small cell lung cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
1753
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: LiH Fan, M.D.
- Phone Number: +8613661599588
- Email: fanlih@aliyun.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, +86200072
- Recruiting
- Shanghai 10th People's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good.
- Patients with single nodule.
- Before IIB period according to the eighth edition of the TNM staging period.
- No mediastinal lymph node metastasis.
- No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments.
- Eastern Cooperative Oncology Group performance status of 0 to 1
- Sufficient organ functions
Exclusion Criteria:
- Active bacterial or fungous infection.
- Simultaneous or metachronous (within the past 5 years) double cancers.
- Patients with contraindications to radiofrequency ablation and inability to complete treatment;
- Women during pregnancy or breast-feeding.
- Uncontrollable diabetes mellitus.
- Patients with severe heart, lung, kidney disease or other systemic diseases who have been judged to have a severe impact on survival or who are pre-assessed to be unable to tolerate thoracoscopic surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mitochondrial therapy with radiofrequency ablation
|
Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites
|
Active Comparator: Surgery
|
Patients will be treated with surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease-free survival
Time Frame: From the date of randomization until the date of first documented progression,assessed up to 60 months
|
From the date of randomization until the date of first documented progression,assessed up to 60 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: From the date of randomization until the date of death from any cause,assessed up to 60 months
|
From the date of randomization until the date of death from any cause,assessed up to 60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 31, 2019
Primary Completion (Anticipated)
January 31, 2024
Study Completion (Anticipated)
January 31, 2024
Study Registration Dates
First Submitted
February 12, 2019
First Submitted That Met QC Criteria
February 12, 2019
First Posted (Actual)
February 15, 2019
Study Record Updates
Last Update Posted (Actual)
February 20, 2019
Last Update Submitted That Met QC Criteria
February 18, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Shanghai
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation
-
xieruiqinCompleted
-
Ruiqin xieCompleted
-
Ruiqin xieCompleted
-
Ruiqin xieCompleted
-
Ruiqin xieRecruitingChanges of Left Atrial Function and Quality of Life in Patients With Left Atrial Appendage OcclusionAtrial FibrillationChina
-
Second Affiliated Hospital, School of Medicine,...Hebei Medical University Fourth Hospital; Zhejiang University; Cancer Hospital...Not yet recruitingUnresectable Metastatic Colorectal Cancer
-
China National Center for Cardiovascular DiseasesEnrolling by invitationHeart Failure | Heart Failure, DiastolicChina
-
The Second Hospital of Hebei Medical UniversityCompletedLeft Atrial Appendage Velocity | Left Atrial Structure | Left Atrial FunctionChina
-
Chinese PLA General HospitalNot yet recruitingPancreatic Neoplasms | Ablation
-
Sheba Medical CenterUnknown